These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1068196)

  • 1. A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity.
    Brady MI; Furminger IG
    J Hyg (Lond); 1976 Oct; 77(2):173-80. PubMed ID: 1068196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protection of ferrets against influenza by immunization with a split influenza vaccine.
    Brady MI; Furminger IG
    Dev Biol Stand; 1975; 28():167-72. PubMed ID: 1126566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural infection with influenza A (H3N2). The development, persistance and effect of antibodies to the surface antigens.
    Smith AJ; Davies JR
    J Hyg (Lond); 1976 Oct; 77(2):271-82. PubMed ID: 185291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.
    Eastwood LM; Jennings R; Milner RD; Potter CW
    J Clin Pathol; 1979 Jun; 32(6):534-7. PubMed ID: 469010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.
    Clark A; Potter CW; Jennings R; Nicholl JP; Langrick AF; Schild GC; Wood JM; Tyrrell DA
    J Hyg (Lond); 1983 Jun; 90(3):351-9. PubMed ID: 6863909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.
    Brady MI; Furminger IG
    J Hyg (Lond); 1976 Oct; 77(2):161-72. PubMed ID: 1068195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the antigenicity and tolerance of an influenza aluminium oxide adsorbate vaccine with an aqueous vaccine.
    Pressler K; Peukert M; Schenk D; Borgoño M
    Pharmatherapeutica; 1982; 3(3):195-200. PubMed ID: 7134227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new, surface-antigen-adsorbed influenza virus vaccine. I. Studies on immunogenicity in hamsters.
    Jennings R; Potter CW; McLaren C; Brady M
    J Hyg (Lond); 1975 Dec; 75(3):341-52. PubMed ID: 1059704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.
    Kilbourne ED
    J Infect Dis; 1976 Oct; 134(4):384-94. PubMed ID: 789791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenicity in hamsters of inactivated vaccines prepared from recombinant influenza viruses.
    Hamzawi M; Jennings R; Potter CW
    J Hyg (Lond); 1981 Dec; 87(3):453-64. PubMed ID: 7031128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new influenza subunit vaccine: reactogenicity and antigenicity in comparison to split and whole virus vaccines (author's transl)].
    Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz A; SchmidtG
    Infection; 1976; 4(2):73-9. PubMed ID: 947849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactions and serologic responses in young children and infants after administration of inactivated monovalent influenza A vaccine.
    Marine WM; Stuart-Harris C
    J Pediatr; 1976 Jan; 88(1):26-30. PubMed ID: 1245938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine.
    Potter CW; Jennings R; Phair JP; Clarke A; Stuart-Harris CH
    J Infect Dis; 1977 Mar; 135(3):423-31. PubMed ID: 850080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.
    Liebowitz D; Lindbloom JD; Brandl JR; Garg SJ; Tucker SN
    Lancet Infect Dis; 2015 Sep; 15(9):1041-1048. PubMed ID: 26333337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model.
    Nerome K; Kumihashi H; Nerome R; Hiromoto Y; Yokota Y; Ueda R; Omoe K; Chiba M
    Dev Biol Stand; 1999; 98():53-63; discussion 73-4. PubMed ID: 10494959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with a new influenza subunit vaccine in adults and children.
    Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ
    Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation.
    Mostow SR; Schoenbaum SC; Dowdle WR; Coleman MT; Kaye HS
    Postgrad Med J; 1973 Mar; 49(569):152-8. PubMed ID: 4802501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.
    Ogra PL; Chow T; Beutner KR; Rubi E; Strussenberg J; DeMello S; Rizzone C
    J Infect Dis; 1977 Apr; 135(4):499-506. PubMed ID: 856917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
    Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R
    Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.